PT -期刊文章盟Avi Gadoth AU -托马斯Kryzer AU -詹姆斯·弗莱尔AU -安德鲁·麦肯AU -万带兰列侬盟肖恩Pittock TI -微管相关蛋白(地图)1 b: PCA-2抗原的免疫球蛋白,生物标志物的小细胞肺癌Carcinoma-related多种神经系统自身免疫性(S41.007) DP - 2017年4月18日TA -神经病学PG - S41.007 VI - 88 IP - 16补充4099 - //www.ez-admanager.com/content/88/16_Supplement/S41.007.short 4100 - //www.ez-admanager.com/content首页/88/16_Supplement/S41.007.full所以Neurology2017 4月18日;88 AB -目的:描述了抗原目标前面描述的浦肯野细胞胞质抗体2型(PCA-2)和扩展其临床、血清学、肿瘤、放射协会。背景:浦肯野细胞抗体类型2 (PCA-2)在2000年被描述为一个免疫球蛋白生物标志物的多种神经系统自身免疫性由小细胞肺癌(SCLC)。其onconeural细胞质抗原(~ 280 - kda)被发现在中欧和外围神经组织和SCLC细胞。这里我们识别自身抗原,并进一步定义临床,PCA-2肿瘤和免疫组织化学特点。设计/方法:档案血清或脑脊液(CSF)标本可以从96年118年连续PCA-2-IgG-seropositive病人确认1993 - 2016。老鼠大脑中定义的自身抗原,溶解产物通过免疫印迹和质谱分析,证实了双使用商业抗体免疫组织化学染色。定义的主要抗原区域使用重组蛋白免疫印迹碎片。结果:免疫球蛋白g在95年96例患者的血清或脑脊液(但在98年的健康或疾病控制受试者的血清标本)绑定到microtubule-associated重组蛋白b(地图)1。少数(17.5%)的患者的免疫球蛋白g也必将MAP1A。PCA-2经常伴随着其他神经自身抗体标记的小细胞癌,包括CRMP-5-IgG(26%)或ANNA-1-IgG (anti-Hu; 13%). Neurological manifestations in 95 patients were (in decreasing frequency): peripheral neuropathy, 53%, cerebellar ataxia, dysmetria or dysarthria, 38%, encephalopathy, 27%. Cancer (majority SCLC) was detected in 66 of 84 evaluated patients (79%). The MAP1B (PCA-2) autoantibody detection rate, among approximately 70,000 patients undergoing service neural autoantibody evaluation in 2015 was 0.024%, equaling amphiphysin-IgG (0.026%) and more common than ANNA-2 (anti-Ri; 0.016%) and PCA-Tr (DNER; 0.006%).Conclusions: MAP1B, the PCA-2 autoantigen, represents a novel target in paraneoplastic neurologic disorders with a high predictive value for SCLC. Its relatively high prevalence, compared with other recognized paraneoplastic neural autoantibodies, justifies its testing in comprehensive paraneoplastic neural autoantibody evaluation.Disclosure: Dr. Gadot has received royalty payments from Mayo Foundation. Dr. Kryzer has nothing to disclose. Dr. Fryer has nothing to disclose. Dr. McKeon has received research support from MedImmune and Euroimmun. Dr. Lennon has received personal compensation from Mayo Foundation-licensed Laboratories. Dr. Pittock's institution has received compensation for Dr. Pittock's activities with Alexion Pharmaceuticals, Medimmune and Chugai Pharma USA. Dr. Pittock and Dr. Pittock's institution stand to receive patent payments that relate to patents for functional AQP4/NMO-IgG assays and NMO-IgG as a cancer marker. Dr. Pittock has received research support from NIH, Alexion Pharmaceuticals and Medimmune related to autoimmune NMO/AQP4 channelopathy.